MENVEO (Meningococcal Group A, C, W-135 and Y conjugate vaccine) - Meningococcal disease

Opinions on drugs - Posted on Jul 29 2024

Reason for request

Modification of the listing conditions

Summary of opinion

Favourable opinion for maintenance of reimbursement in the active immunisation of individuals against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y, in accordance with the current HAS recommendations of 7 March 2024 and 27 June 2024.

Clinical Benefit

Substantial

The Committee deems that updating of the vaccine strategy in accordance with the current HAS recommendations of 7 March 2024 and 27 June 2024 is not of a nature to modify the clinical benefit, which remains substantial in the active immun isation of individuals from 2 years of age against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135 and Y.

Clinical Added Value

no clinical added value

Updating of the vaccine strategy in accordance with the current HAS recommendations of 7 March 2024 and 27 June 2024 is not of a nature to modify the clinical added value in the active immunisation of individuals against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135 and Y (no clinical added value (CAV V)) in individuals from 2 years of age according to the opinions of 1 December 2010 and 8 January 2014).